GT Biopharma (GTBP) Treasury Shares (2022 - 2025)

GT Biopharma (GTBP) posted quarterly Treasury Shares of $6301.0 for Q2 2025, up 126.82% quarter-over-quarter from $2778.0 in Q1 2024.

GT Biopharma (GTBP) Treasury Shares (2022 - 2025) Analysis & Trends

GT Biopharma (GTBP) has reported Treasury Shares for 4 consecutive years, with $6301.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Treasury Shares changed N/A year-over-year to $6301.0; the TTM figure through Jun 2025 stood at $6301.0 (changed N/A YoY), while the FY2023 annual figure was $8085.0, down 97.06% from the prior year.
Treasury Shares grew to $6301.0 in Q2 2025 per GTBP's latest filing, from $2778.0 in the prior quarter.
Across five years, Treasury Shares topped out at $625605.0 in Q3 2022 and bottomed at $2778.0 in Q1 2024.
Historically, Treasury Shares has averaged $166054.3 across 4 years, with a median of $53225.0 in 2023.
On a YoY basis, Treasury Shares climbed as much as 72.18% in 2023 and fell as far as 97.06% in 2023.
GT Biopharma's Treasury Shares stood at $275101.0 in 2022, then plunged by 97.06% to $8085.0 in 2023, then plunged by 65.64% to $2778.0 in 2024, then jumped by 126.82% to $6301.0 in 2025.
Business Quant data shows GTBP's Treasury Shares at $6301.0 in Q2 2025, $2778.0 in Q1 2024, and $8085.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	GT Biopharma	8.64 Mn	8.64 Mn	-	-

Download Data